E E Voest
Overview
Explore the profile of E E Voest including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
1994
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
van Waalwijk van Doorn-Khosrovani S, Pisters-van Roy A, van Saase L, van der Graaff M, Gijzen J, Sleijfer S, et al.
Ann Oncol
. 2019 May;
30(5):663-665.
PMID: 31038154
No abstract available.
12.
Bijlsma R, Wouters R, Wessels H, May A, Ausems M, Voest E, et al.
Psychooncology
. 2018 Feb;
27(4):1327-1333.
PMID: 29471587
Objective: Next-generation sequencing (NGS) is increasingly being employed in the context of personalized cancer treatment. Anticipating unsolicited findings that may arise during a NGS procedure is a key consideration; however,...
13.
van der Velden D, van Herpen C, van Laarhoven H, Smit E, Groen H, Willems S, et al.
Ann Oncol
. 2017 Oct;
28(12):3070-3075.
PMID: 29045504
Background: Due to rapid technical advances, steeply declining sequencing costs, and the ever-increasing number of targeted therapies, it can be expected that extensive tumor sequencing such as whole-exome and whole-genome...
14.
Snoeren N, van Hillegersberg R, Schouten S, Bergman A, van Werkhoven E, Dalesio O, et al.
Neoplasia
. 2017 Jan;
19(2):93-99.
PMID: 28088688
Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF). Recurrence after resection of colorectal liver metastases (CRLMs), presumably caused by VEGF-mediated outgrowth of micrometastases, might decrease when...
15.
Cirkel G, Weeber F, Bins S, Gadellaa-van Hooijdonk C, van Werkhoven E, Willems S, et al.
Ann Oncol
. 2016 May;
27(8):1638-43.
PMID: 27234642
Background: Early signs of efficacy are critical in drug development. Response Evaluation Criteria in Solid Tumors (RECIST) are commonly used to determine the efficacy of anti-cancer therapy in clinical trials....
16.
van Jaarsveld M, Houthuijzen J, Voest E
Oncogene
. 2015 Dec;
35(31):4021-35.
PMID: 26640151
Over the past decade the importance of lipids for cancer cell metabolism and cancer-related processes such as proliferation, metastasis and chemotherapy resistance has become more apparent. The mechanisms by which...
17.
Milojkovic Kerklaan B, Lolkema M, Devriese L, Voest E, Nol-Boekel A, Mergui-Roelvink M, et al.
Br J Cancer
. 2015 Aug;
113(5):706-15.
PMID: 26291057
Background: This phase I study evaluated the safety, tolerability, maximum tolerated dose (MTD) and pharmacokinetics of two dosing schedules of oral topotecan in combination with pazopanib in patients with advanced...
18.
van der Sluis P, Ubink I, van der Horst S, Boonstra J, Voest E, Ruurda J, et al.
Ann Surg Oncol
. 2015 Jan;
22(5):1555-63.
PMID: 25564156
Background: Perioperative epirubicin, cisplatin, and capecitabine (ECC) chemotherapy was evaluated in patients who underwent esophageal resection for adenocarcinoma of the esophagus or gastroesophageal junction (GEJ). Methods: A cohort of 93...
19.
Lankheet N, Kloth J, Gadellaa-van Hooijdonk C, Cirkel G, Mathijssen R, Lolkema M, et al.
Br J Cancer
. 2014 Apr;
110(10):2441-9.
PMID: 24736581
Background: Plasma exposure of sunitinib shows large inter-individual variation. Therefore, a pharmacokinetic (PK) study was performed to determine safety and feasibility of sunitinib dosing based on PK levels. Methods: Patients...
20.
Cassier P, Polivka V, Judson I, Soria J, Penel N, Marsoni S, et al.
Ann Oncol
. 2014 Mar;
25(6):1222-8.
PMID: 24608201
Background: Although sarcomas account for only 1% of all solid tumours, patients with sarcomas comprise a larger proportion of patients entering phase I trials, due to the limited number of...